1
|
Ge Y, Xu X, Cao M, Liu B, Wang Y, Liao P, Wang J, Chen Y, Yuan H, Chen G. Nasal Drug Delivery and Nose-to-Brain Delivery Technology Development Status and Trend Analysis: Based on Questionnaire Survey and Patent Analysis. Pharmaceutics 2024; 16:929. [PMID: 39065623 PMCID: PMC11279750 DOI: 10.3390/pharmaceutics16070929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2024] [Revised: 07/04/2024] [Accepted: 07/09/2024] [Indexed: 07/28/2024] Open
Abstract
Nasal administration is a non-invasive method of drug delivery that offers several advantages, including rapid onset of action, ease of use, no first-pass effect, and fewer side effects. On this basis, nose-to-brain delivery technology offers a new method for drug delivery to the brain and central nervous system, which has attracted widespread attention. In this paper, the development status and trends of nasal drug delivery and nose-to-brain delivery technology are deeply analyzed through multiple dimensions: literature research, questionnaire surveys, and patent analysis. First, FDA-approved nasal formulations for nose-to-brain delivery were combed. Second, we collected a large amount of relevant information about nasal drug delivery through a questionnaire survey of 165 pharmaceutical industry practitioners in 28 provinces and 161 different organizations in China. Third, and most importantly, we conducted a patent analysis of approximately 700+ patents related to nose-to-brain delivery, both domestically and internationally. This analysis was conducted in terms of patent application trends, technology life cycle, technology composition, and technology evolution. The LDA topic model was employed to identify technological topics in each time window (1990-2023), and the five key major evolution paths were extracted. The research results in this paper will provide useful references for relevant researchers and enterprises in the pharmaceutical industry, promoting the further development and application of nasal drug delivery and nose-to-brain delivery technology.
Collapse
Affiliation(s)
- Yuanyuan Ge
- School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; (Y.G.); (B.L.); (Y.W.)
- Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China; (M.C.); (P.L.); (J.W.); (Y.C.)
| | - Xingying Xu
- Shanghai Library (Institute of Scientific and Technical Information of Shanghai), Shanghai 200031, China;
| | - Meng Cao
- Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China; (M.C.); (P.L.); (J.W.); (Y.C.)
| | - Baijun Liu
- School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; (Y.G.); (B.L.); (Y.W.)
| | - Ying Wang
- School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; (Y.G.); (B.L.); (Y.W.)
| | - Ping Liao
- Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China; (M.C.); (P.L.); (J.W.); (Y.C.)
| | - Jiajing Wang
- Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China; (M.C.); (P.L.); (J.W.); (Y.C.)
| | - Yifei Chen
- Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China; (M.C.); (P.L.); (J.W.); (Y.C.)
| | - Hongmei Yuan
- School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; (Y.G.); (B.L.); (Y.W.)
| | - Guiliang Chen
- Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China; (M.C.); (P.L.); (J.W.); (Y.C.)
| |
Collapse
|
2
|
Vaiss DP, Rodrigues JL, Yurgel VC, do Carmo Guedes F, da Matta LLM, Barros PAB, Vaz GR, Dos Santos RN, Matte BF, Kupski L, Garda-Buffon J, Bidone J, Muccillo-Baisch AL, Sonvico F, Dora CL. Curcumin and quercetin co-encapsulated in nanoemulsions for nasal administration: A promising therapeutic and prophylactic treatment for viral respiratory infections. Eur J Pharm Sci 2024; 197:106766. [PMID: 38615970 DOI: 10.1016/j.ejps.2024.106766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 03/19/2024] [Accepted: 04/12/2024] [Indexed: 04/16/2024]
Abstract
One of the most frequent causes of respiratory infections are viruses. Viruses reaching the airways can be absorbed by the human body through the respiratory mucosa and mainly infect lung cells. Several viral infections are not yet curable, such as coronavirus-2 (SARS-CoV-2). Furthermore, the side effect of synthetic antiviral drugs and reduced efficacy against resistant variants have reinforced the search for alternative and effective treatment options, such as plant-derived antiviral molecules. Curcumin (CUR) and quercetin (QUE) are two natural compounds that have been widely studied for their health benefits, such as antiviral and anti-inflammatory activity. However, poor oral bioavailability limits the clinical applications of these natural compounds. In this work, nanoemulsions (NE) co-encapsulating CUR and QUE designed for nasal administration were developed as promising prophylactic and therapeutic treatments for viral respiratory infections. The NEs were prepared by high-pressure homogenization combined with the phase inversion temperature technique and evaluated for their physical and chemical characteristics. In vitro assays were performed to evaluate the nanoemulsion retention into the porcine nasal mucosa. In addition, the CUR and QUE-loaded NE antiviral activity was tested against a murine β-COV, namely MHV-3. The results evidenced that CUR and QUE loaded NE had a particle size of 400 nm and retention in the porcine nasal mucosa. The antiviral activity of the NEs showed a percentage of inhibition of around 99 %, indicating that the developed NEs has interesting properties as a therapeutic and prophylactic treatment against viral respiratory infections.
Collapse
Affiliation(s)
- Daniela Pastorim Vaiss
- Postgraduate Program in Health Sciences, Federal University of Rio Grande, Rio Grande 96203-900, Brazil
| | - Jamile Lima Rodrigues
- Graduate Program in Food Science and Engineering, Federal University of Rio Grande, Rio Grande 96203-900 Brazil, RS, Brazil
| | - Virginia Campello Yurgel
- Postgraduate Program in Health Sciences, Federal University of Rio Grande, Rio Grande 96203-900, Brazil
| | - Frank do Carmo Guedes
- Postgraduate Program in Health Sciences, Federal University of Rio Grande, Rio Grande 96203-900, Brazil
| | | | | | - Gustavo Richter Vaz
- Postgraduate Program in Health Sciences, Federal University of Rio Grande, Rio Grande 96203-900, Brazil
| | - Raíssa Nunes Dos Santos
- Virology Laboratory of the Biotechnology Startup Núcleo Vitro, Porto Alegre 91040-600, Brazil; Laboratory of Bioinformatics and Biotechnology, Campus de Gurupi, Federal University of Tocantins, Gurupi 77402-970, Brazil
| | - Bibiana Franzen Matte
- Virology Laboratory of the Biotechnology Startup Núcleo Vitro, Porto Alegre 91040-600, Brazil
| | - Larine Kupski
- Laboratory for Mycotoxins and Food Science, School of Chemistry and Food, Federal University of Rio Grande - FURG, Italy Avenue 8 km, Campus Carreiros, 96203-900 Rio Grande, RS, Brazil
| | - Jaqueline Garda-Buffon
- Laboratory for Mycotoxins and Food Science, School of Chemistry and Food, Federal University of Rio Grande - FURG, Italy Avenue 8 km, Campus Carreiros, 96203-900 Rio Grande, RS, Brazil
| | - Juliana Bidone
- Center of Chemical, Pharmaceutical and Food Sciences, Federal University of Pelotas, Campus Capão do Leão, 96010-610 Pelotas, RS, Brazil
| | - Ana Luiza Muccillo-Baisch
- Postgraduate Program in Health Sciences, Federal University of Rio Grande, Rio Grande 96203-900, Brazil
| | - Fabio Sonvico
- Food and Drug Department, University of Parma, Parma, Italy.
| | - Cristiana Lima Dora
- Postgraduate Program in Health Sciences, Federal University of Rio Grande, Rio Grande 96203-900, Brazil.
| |
Collapse
|
3
|
Gandhi S, Shastri DH, Shah J, Nair AB, Jacob S. Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport. Pharmaceutics 2024; 16:481. [PMID: 38675142 PMCID: PMC11055100 DOI: 10.3390/pharmaceutics16040481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Revised: 03/21/2024] [Accepted: 03/27/2024] [Indexed: 04/28/2024] Open
Abstract
The nose-to-brain drug-delivery system has emerged as a promising strategy to overcome the challenges associated with conventional drug administration for central nervous system disorders. This emerging field is driven by the anatomical advantages of the nasal route, enabling the direct transport of drugs from the nasal cavity to the brain, thereby circumventing the blood-brain barrier. This review highlights the significance of the anatomical features of the nasal cavity, emphasizing its high permeability and rich blood supply that facilitate rapid drug absorption and onset of action, rendering it a promising domain for neurological therapeutics. Exploring recent developments and innovations in different nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, micelles, nanoemulsions, nanosuspensions, carbon nanotubes, mesoporous silica nanoparticles, and nanogels unveils their diverse functions in improving drug-delivery efficiency and targeting specificity within this system. To minimize the potential risk of nanoparticle-induced toxicity in the nasal mucosa, this article also delves into the latest advancements in the formulation strategies commonly involving surface modifications, incorporating cutting-edge materials, the adjustment of particle properties, and the development of novel formulations to improve drug stability, release kinetics, and targeting specificity. These approaches aim to enhance drug absorption while minimizing adverse effects. These strategies hold the potential to catalyze the advancement of safer and more efficient nose-to-brain drug-delivery systems, consequently revolutionizing treatments for neurological disorders. This review provides a valuable resource for researchers, clinicians, and pharmaceutical-industry professionals seeking to advance the development of effective and safe therapies for central nervous system disorders.
Collapse
Affiliation(s)
- Shivani Gandhi
- Department of Pharmaceutics, K. B. Institute of Pharmaceutical Education and Research, A Constituent College of Kadi Sarva Vishwavidyalaya, Sarva Vidyalaya Kelavani Mandal, Gh-6, Sector-23, Kadi Campus, Gandhinagar 382023, Gujarat, India;
| | - Divyesh H. Shastri
- Department of Pharmaceutics, K. B. Institute of Pharmaceutical Education and Research, A Constituent College of Kadi Sarva Vishwavidyalaya, Sarva Vidyalaya Kelavani Mandal, Gh-6, Sector-23, Kadi Campus, Gandhinagar 382023, Gujarat, India;
| | - Jigar Shah
- Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India;
| | - Anroop B. Nair
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia;
| | - Shery Jacob
- Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman 4184, United Arab Emirates;
| |
Collapse
|
4
|
Pieren DKJ, Benítez-Martínez A, Genescà M. Targeting HIV persistence in the tissue. Curr Opin HIV AIDS 2024; 19:69-78. [PMID: 38169333 DOI: 10.1097/coh.0000000000000836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
PURPOSE OF REVIEW The complex nature and distribution of the HIV reservoir in tissue of people with HIV remains one of the major obstacles to achieve the elimination of HIV persistence. Challenges include the tissue-specific states of latency and viral persistence, which translates into high levels of reservoir heterogeneity. Moreover, the best strategies to reach and eliminate these reservoirs may differ based on the intrinsic characteristics of the cellular and anatomical reservoir to reach. RECENT FINDINGS While major focus has been undertaken for lymphoid tissues and follicular T helper cells, evidence of viral persistence in HIV and non-HIV antigen-specific CD4 + T cells and macrophages resident in multiple tissues providing long-term protection presents new challenges in the quest for an HIV cure. Considering the microenvironments where these cellular reservoirs persist opens new venues for the delivery of drugs and immunotherapies to target these niches. New tools, such as single-cell RNA sequencing, CRISPR screenings, mRNA technology or tissue organoids are quickly developing and providing detailed information about the complex nature of the tissue reservoirs. SUMMARY Targeting persistence in tissue reservoirs represents a complex but essential step towards achieving HIV cure. Combinatorial strategies, particularly during the early phases of infection to impact initial reservoirs, capable of reaching and reactivating multiple long-lived reservoirs in the body may lead the path.
Collapse
Affiliation(s)
- Daan K J Pieren
- Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | | | | |
Collapse
|
5
|
Aguilar-Hernández G, López-Romero BA, Nicolás-García M, Nolasco-González Y, García-Galindo HS, Montalvo-González E. Nanosuspensions as carriers of active ingredients: Chemical composition, development methods, and their biological activities. Food Res Int 2023; 174:113583. [PMID: 37986449 DOI: 10.1016/j.foodres.2023.113583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 10/06/2023] [Accepted: 10/13/2023] [Indexed: 11/22/2023]
Abstract
Nanosuspensions (NSps) are colloidal dispersions of particles that have the potential to solve the delivery problems of active ingredients associated with their low solubility in water or instability due to environmental factors. It is essential to consider their chemical composition and preparation methods because they directly influence drug loading, size, morphology, solubility, and stability; these characteristics of nanosuspensions influence the delivery and bioavailability of active ingredients. NSps provides high loading of drugs, protection against degrading agents, rapid dissolution, high particle stability, and high bioavailability of active ingredients across biological membranes. In addition, they provide lower toxicity compared to other nanocarriers, such as liposomes or polymeric nanoparticles, and can modify the pharmacokinetic profiles, thus improving their safety and efficacy. The present review aims to address all aspects related to the composition of NSps, the different methods for their production, and the main factors affecting their stability. Moreover, recent studies are described as carriers of active ingredients and their biological activities.
Collapse
Affiliation(s)
- Gabriela Aguilar-Hernández
- División de Ciencias Agropecuarias e Ingenierías, Centro Universitario de los Altos, Universidad de Guadalajara, Av. Rafael Casillas Aceves 1200, Tepatitlán de Morelos 47600, Jalisco, Mexico
| | - Brandon A López-Romero
- Laboratorio Integral de Investigación en Alimentos, Tecnológico Nacional de México/Instituto Tecnológico de Tepic, Av. Tecnológico 2595, Tepic 63175, Nayarit, Mexico
| | - Mayra Nicolás-García
- Ingeniería en Industrias Alimentarias, Tecnológico Nacional de México/Instituto Tecnológico Superior de Teziutlán, Fracción I y II, Aire Libre S/N, 73960, Teziutlán, Puebla, México
| | - Yolanda Nolasco-González
- Laboratorio Integral de Investigación en Alimentos, Tecnológico Nacional de México/Instituto Tecnológico de Tepic, Av. Tecnológico 2595, Tepic 63175, Nayarit, Mexico; Instituto Nacional de Investigaciones Forestales, Agrícolas y Pecuarias, Campo Experimental Santiago Ixcuintla, Km 6 Carr. México-Nogales, Santiago Ixcuintla, 63300, Nayarit, Mexico
| | - Hugo S García-Galindo
- Tecnológico Nacional de México/Institito Tecnológico de Veracruz. nstituto Tecnológico de Veracruz, Unidad de Investigación y Desarrollo de Alimentos, Av. Miguel Ángel de Quevedo 2779, Veracruz 91897, Veracruz, Mexico
| | - Efigenia Montalvo-González
- Laboratorio Integral de Investigación en Alimentos, Tecnológico Nacional de México/Instituto Tecnológico de Tepic, Av. Tecnológico 2595, Tepic 63175, Nayarit, Mexico.
| |
Collapse
|